A genetic polymorphism of MAO-B modifies the association of cigarette smoking and Parkinson's disease

被引：77
|
作者：
Checkoway, H
Franklin, GM
Costa-Mallen, P
Smith-Weller, T
Dilley, J
Swanson, PD
Costa, LG
机构：
[1] Univ Washington, Dept Environm Hlth, Seattle, WA 98195 USA
[2] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[3] Univ Washington, Dept Neurol, Seattle, WA 98195 USA
来源：
NEUROLOGY | 1998年 / 50卷 / 05期
关键词：
D O I：
10.1212/WNL.50.5.1458
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
In a population-based case-control study, we found a reversal of the association of cigarette smoking with Parkinson's disease (PD) in relation to the monoamine oxidase B intron 13 genetic polymorphism. A reduced PD risk related to pack-years of smoking was detected for persons with the G allele, whereas an opposite effect was found among persons with the A allele. These results indicate an unexplained interaction between cigarette smoking and this genetic polymorphism.
引用
收藏
页码：1458 / 1461
页数：4
相关论文
共 50 条
  • [31] Metabolic Control Analysis in a Cellular Model of Elevated MAO-B: Relevance to Parkinson’s Disease
    Jyothi K. Mallajosyula
    Shankar J. Chinta
    Subramanian Rajagopalan
    David G. Nicholls
    Julie K. Andersen
    Neurotoxicity Research, 2009, 16 : 186 - 193
  • [32] Rotigotine in combination with a MAO-B inhibitor in early Parkinson's disease: A post hoc analysis
    Asgharnejad, M.
    Bauer, L.
    Grieger, F.
    Boroojerdi, B.
    MOVEMENT DISORDERS, 2014, 29 : S225 - S226
  • [33] Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson’s disease
    John P. M. Finberg
    Journal of Neural Transmission, 2019, 126 : 433 - 448
  • [34] Anti-obesity effect of irreversible MAO-B inhibitors in patients with Parkinson's disease
    Liang, Siyu
    Sun, Yuxin
    Chen, Shi
    Pan, Hui
    NUTRITION & DIABETES, 2024, 14 (01):
  • [35] MAO-B inhibitors and dopamine agonists as initial treatment in Parkinson's disease: a naturalistic survey
    Kuusisto, H.
    Mattila, T.
    Keranen, T.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 115 - 115
  • [36] MAO-B inhibitors and dopamine agonists as initial treatment in Parkinson's disease: A naturalistic survey
    Keraenen, T.
    Mattila, T.
    Kuusisto, H.
    MOVEMENT DISORDERS, 2010, 25 (07) : S402 - S402
  • [37] Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease
    Finberg, John P. M.
    JOURNAL OF NEURAL TRANSMISSION, 2019, 126 (04) : 433 - 448
  • [38] Effects of combined MAO-B inhibitors and levodopa vs. rnonotherapy in Parkinson's disease
    Krishna, Rakhee
    Ali, Manal
    Moustafa, Ahmed A.
    FRONTIERS IN AGING NEUROSCIENCE, 2014, 6
  • [39] Metabolic Control Analysis in a Cellular Model of Elevated MAO-B: Relevance to Parkinson's Disease
    Mallajosyula, Jyothi K.
    Chinta, Shankar J.
    Rajagopalan, Subramanian
    Nicholls, David G.
    Andersen, Julie K.
    NEUROTOXICITY RESEARCH, 2009, 16 (03) : 186 - 193
  • [40] Genetic Variants and Levodopa Response in Parkinson's disease (PD) : Insights from MAO-B and DAT1 Polymorphisms
    Sarkar, S.
    Biswas, A.
    Ansari, S.
    Sengupta, S.
    Choudhury, S.
    Banerjee, R.
    Chatterjee, S.
    Dey, S.
    Kumar, H.
    MOVEMENT DISORDERS, 2024, 39 : S846 - S846
12345